O-GlcNAc

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Protein O-GlcNAcase, Neurological disorders, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Dementia

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Protein O-GlcNAcase, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Tau protein

LAUSANNE, Switzerland and SAN FRANSICO, July 28, 2021 /PRNewswire/ -- Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer's Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.
  • The Peter Davies Memorial Symposium: The Future of Tau Based Therapies (preclinical, early phase, current studies, future)

M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Biology, Mannose 6-phosphate, Organophosphates, Lysosome, O-GlcNAc, Phosphotransferase, GNPTG, N-acetylglucosamine-1-phosphate transferase, Mucolipidosis II, M6P Therapeutics, MUCOLIPIDOSIS II, M6P THERAPEUTICS

Krysiak continued, \xe2\x80\x9cTogether, these results provide a strong foundation for our broader gene therapy pipeline, which leverages our S1S3 bicistronic platform to enhance M6P content across lysosomal enzymes.

Key Points: 
  • Krysiak continued, \xe2\x80\x9cTogether, these results provide a strong foundation for our broader gene therapy pipeline, which leverages our S1S3 bicistronic platform to enhance M6P content across lysosomal enzymes.
  • The mutation leads to GlcNAc-1-phosphotransferase deficiency and inability to phosphorylate (add mannose 6-phosphate, or M6P) lysosomal enzymes.
  • This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases.
  • M6P Therapeutics\xe2\x80\x99 mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community.